No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 10.7x · 10Y median 5.9x · 82nd percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T22:33:29.149Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T22:33:29.149Z. Latest historical point 2021-11-12. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T22:33:29.149Z. Latest historical point 2021-11-12. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Alpha Teknova, Inc. (TKNO) stock was $8.75 as of Oct 6, 2026, 4:00 PM EDT, down 2.78% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +59.2% · 3-year avg +59.9%/yr · 5-year avg -18.1%/yr
Alpha Teknova, Inc. supplies vital scientific reagents to the life sciences sector across both the United States and international markets.
Drug Manufacturers - Specialty & Generic · Hollister, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.06
Revenue Est.
$11.72M
Last Quarter Results
EPS
$-0.05
vs Estimate
$-0.07
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1TKNO | $469.12M | $8.75 | -2.78% | +59.22% | -18.15% | N/A | N/A |
| 2KMDA | $467.90M | $8.11 | +1.37% | +23.24% | +10.36% | +5.44% | vs TKNO |
| 3CERS | $471.57M | $2.34 | +0.00% | +48.76% | -17.30% | -9.37% | vs TKNO |
| 4ARVN | $471.65M | $7.31 | -2.01% | -22.28% | -38.16% | N/A | vs TKNO |
| 5DRUG | $472.23M | $48.25 | -3.09% | -6.49% | +6.76% | N/A | vs TKNO |
| 6SGHT | $465.75M | $8.56 | -4.04% | +169.84% | -18.69% | N/A | vs TKNO |
forward FY estimate
N/A
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
$12.19M
vs Estimate
$10.95M
Consensus Rating
Based on 6 analysts
Average Price Target
$9.00
+2.9% upside
Low
$7.00
Current
$8.75
High
$12.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.09 | $-0.07 | $-0.06 | 1 |
| Quarter ending Dec 2026 | $-0.09 | $-0.09 | $-0.08 | 4 |
| Quarter ending Mar 2027 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Quarter ending Jun 2027 | $-0.06 | $-0.06 | $-0.06 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.33 | $-0.30 | $-0.26 | 3 |
| FY 2027 | $-0.31 | $-0.26 | $-0.21 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $11.62M | $11.72M | $11.82M | 4 |
| Quarter ending Dec 2026 | $10.93M | $11.03M | $11.13M | 4 |
| Quarter ending Mar 2027 | $12.03M | $12.32M | $12.52M | 2 |
| Quarter ending Jun 2027 | $13.26M | $13.58M | $13.80M | 2 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $45.95M | $46.00M | $46.05M | 6 |
| FY 2027 | $52.35M | $52.45M | $52.55M | 6 |
